Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


14 Items
Title  Creator  Group name  Publishing year 
Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine Hebert et al. EquipeJPP 2024-06-03
"One Method to Label Them All": A Single Fully Automated Protocol for GMP-Compliant 68Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617 Fouillet et al. EquipeJPP 2024
Identification of 18F-FDG PET/CT Parameters Associated with Weight Loss in Patients with Esophageal Cancer Galvez et al. EquipeAD 2023-07-05
Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case Barakat et al. EquipeJPP 2023-07
225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic Rubira et al. EquipeJPP 2023-03-24
From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group's experience Pouget et al. EquipeJPP 2022
Development and Implementation of a Professional Practices Evaluation during Radiopharmaceuticals Administration Donzé et al. EquipeJPP 2022-11-10
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH) Deshayes et al. EquipeJPP 2022-12-22
177 Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods Donzé et al. EquipeJPP 2022-09-13
Whole body planar and 3D quantitative imaging after 177Lu-DOTATATE on CZT SPECT/CT device with MEHRS collimator. First report Deshayes et al. EquipeJPP 2021
Hepatobiliary Scintigraphy and Glass 90Y Radioembolization with Personalized Dosimetry: Dynamic Changes in Treated and Nontreated Liver Allimant et al. EquipeJPP 2021-05-21
Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0 Santoro et al. EquipeJPP 2021-01-04
Comparison of commercial dosimetric software platforms in patients treated with 177 Lu-DOTATATE for peptide receptor radionuclide therapy Mora-Ramirez et al. EquipeJPP 2020-09
Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study Deshayes et al. EquipeAD Oct 2019
14 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés